AbbVie Inc.

And thank you for standing by. Welcome to the AbbVie second quarter 2022 earnings conference call. All participants will be able to listen only and tell the question and answer portion of this call. You may ask a question by pressing star one on your phone. I'd now like to introduce Ms. Liz Shea, Vice President, Head of Investor Relations.

Good morning, and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer, Rob Michaels, Vice Chairman and President, Jeff Stewart, Executive Vice President, Chief Commercial Officer, and Tom Hudson, Senior Vice President, R&D, and Chief Scientific Officer. Joining us for the Q&A portion of the call are Laura Schumacher, Vice Chairman, External Affairs, Chief Legal Officer and Corporate Secretary, Kerry Strom, Senior Vice President and President of Global Allergan Aesthetics, Scott Rentz, Senior Vice President and Chief Financial Officer, Neil Gallagher, Vice President, Development and Chief Medical Officer, and Rupal Thakkar, Vice President, Global Regulatory Affairs. Before we get started, I'll note that some statements we make today may be considered forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Add the caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statement. Additional information about these risks and uncertainties is included in our SEC filings. ABBYY undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand ABBYY's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll now turn the call over to Rick.

Thank you, Liz. Good morning, everyone, and thank you for joining us today. I'll briefly comment on our overall performance, then Jeff, Tom, and Rob will review our second quarter business highlights, pipeline progress, and financial results in more detail. AbbVie delivered another strong quarter with adjusted earnings per share of $3.37, exceeding our expectations. Total net revenues of approximately $14.6 billion was up 6.1% on an operational basis, in line with our expectations. This performance reflects robust double-digit operational sales growth from Immunology, where SkyRisi is exceeding our expectations with impressive market share gains in both psoriasis and PSA. SkyRisi's recent U.S. approval in Crohn's disease will add yet another source of long-term growth. As a result of the strong performance we've seen in the first half of the year, we are raising our full-year guidance for Skyrizzy. Renvoke is also demonstrating strong growth. RA continues to perform in line with our expectations following the label update, and we're making very good progress with all of the newly launched indications, including PSA, AS, atopic dermatitis, and ulcerative colitis, which collectively represent a significant long-term growth opportunity. Neuroscience is another area with outstanding performance. VALAR, Botox Therapeutics, UBrelvi, and QLIPTA each demonstrated double-digit sequential sales growth. Pending regulatory approvals for VALAR and major depressive disorder, QLIPTA and chronic migraine, and 951 for the treatment of advanced Parkinson's disease represent additional near-term growth opportunities for our neuroscience portfolio. Turning now to aesthetics, Botox Cosmetics once again performed very well, with sales up more than 20% on an operational basis. Demand for toxins remained strong with high teens growth in the U.S., despite inflation dynamics. As expected, Juvenile performance was negatively impacted by COVID-related lockdowns in China, as well as the suspension of our operations in Russia. Additionally, in the U.S., We had a difficult prior year comparison with a promotional event that we ran last year. We also saw a modest impact in the quarter due to economic pressures. We continue to expect positive full-year growth for Juvedome, driven by the lessening COVID impact in China and two new filler launches in the U.S., which will benefit growth in the second half of the year. In hematological oncology, Imbruvica continues to be unfavorably impacted by a delayed market recovery for new patients starting therapy in CLL and increasing competition. These ongoing dynamics will have an impact on Imbruvica's projected 2022 revenues. As a result, we will be adjusting our four-year guidance to reflect these impacts. Benclecta continues to demonstrate robust share performance in both CLL and AML, with sales up double digits on an operational basis. Van Clexta also has registrational studies ongoing and additional attractive indications such as multiple myeloma in the T11-14 patient population with Phase III data forthcoming, as well as high-risk MDS. Additionally, we have an exciting and diverse pipeline of promising new therapies to address critical unmet needs in both blood cancers and solid tumors, which are expected to support the next wave of AbbVie's growth in oncology. In summary, the diversity of our portfolio once again allowed us to deliver another strong performance, despite the challenges we see in the CLL market and increasing Imbruvica competition. Skyrizi and Rynbook are performing exceptionally well and are on pace to deliver approximately $7.5 billion in combined sales this year. Neuroscience demonstrated balanced double-digit growth driven by migraine and Baylor, and continued robust Botox cosmetic growth offset some of the U.S. inflationary impact to our filler and body contouring portfolios. As a result, we are confirming our full year 2022 adjusted earnings per share guidance of $13.78 to $13.98, representing growth of more than 17% at the midpoint. With that, I'll turn the call over to Jeff for additional comments or commercial highlights.